Xeris Biopharma Holdings, Inc.
US ˙ NasdaqGS ˙ US98422E1038

SecurityXERS / Xeris Biopharma Holdings, Inc.
InsiderJohn Johnson
This page shows the track record and history of JOHNSON JOHN insider trades in Xeris Biopharma Holdings, Inc.. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company. It is illegal for insiders to make trades in their companies based on material, non-public information ("MNPI"). This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.
Insider Purchases - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made by John Johnson in XERS / Xeris Biopharma Holdings, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

XERS / Xeris Biopharma Holdings, Inc. Insider Trades
Insider Sales - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made by John Johnson in XERS / Xeris Biopharma Holdings, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-12-19 135,400 7.2158 135,400 7.2158 977,019 95 5.2900 -260,753 -26.69
2025-08-13 107,500 7.3159 107,500 7.3159 786,459

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

XERS / Xeris Biopharma Holdings, Inc. Insider Trades
Insider Transaction History
File
Date
Trade
Date
Form Insider Ticker Security Title Code 10b5-1 Direct Exercise
Price
Unit
Price
Units
Changed
Value
Changed (1K)
Remaining
Options
Remaining
Shares
2026-06-05 2026-06-04 4 JOHNSON JOHN XERS Common Stock A - Award D 24,193 707,276
2026-06-05 2026-06-04 4 JOHNSON JOHN XERS Common Stock S - Sale D 6.0948 -15,000 -91 683,083
2025-12-19 2025-12-19 4 JOHNSON JOHN XERS Common Stock S - Sale D 7.2158 -135,400 -977 698,083
2025-08-15 2025-08-13 4 JOHNSON JOHN XERS Common Stock S - Sale D 7.3159 -107,500 -786 833,483
2025-06-04 2025-06-04 4 JOHNSON JOHN XERS Common Stock A - Award D 50,000 940,983
2024-06-05 2024-06-05 4 JOHNSON JOHN XERS Common Stock A - Award D 50,000 890,983
2024-04-01 2024-03-15 4 JOHNSON JOHN XERS Common Stock J - Other D 89,571 840,983
2024-03-18 2024-03-18 4 JOHNSON JOHN XERS Common Stock M - Exercise D 1.9900 215,600 429 751,412
2023-06-07 2023-06-07 4 JOHNSON JOHN XERS Common Stock A - Award D 42,500 535,812
2022-06-09 2022-06-08 4 JOHNSON JOHN XERS Common Stock A - Award D 15,000 493,312
2021-10-08 2021-10-05 4/A JOHNSON JOHN XERS Stock Option (Right to Buy) A - Award D 2.37 2.3700 19,650 47 19,650
2021-10-08 2021-10-05 4/A JOHNSON JOHN XERS Stock Option (Right to Buy) A - Award D 2.43 68,600 68,600
2021-10-08 2021-10-05 4/A JOHNSON JOHN XERS Stock Option (Right to Buy) A - Award D 1.99 215,600 215,600
2021-10-08 2021-10-05 4/A JOHNSON JOHN XERS Stock Option (Right to Buy) A - Award D 7.02 31,360 31,360
2021-10-08 2021-10-05 4/A JOHNSON JOHN XERS Stock Option (Right to Buy) A - Award D 9.89 31,360 31,360
2021-10-08 2021-10-05 4/A JOHNSON JOHN XERS Stock Option (Right to Buy) A - Award D 5.62 31,360 31,360
2021-10-08 2021-10-05 4/A JOHNSON JOHN XERS Stock Option (Right to Buy) A - Award D 22.39 10,367 10,367
2021-10-08 2021-10-05 4/A JOHNSON JOHN XERS Common Stock A - Award D 478,312 478,312
2021-10-05 2021-10-05 4 JOHNSON JOHN XERS Stock Option (Right to Buy) A - Award D 2.43 68,600 68,600
2021-10-05 2021-10-05 4 JOHNSON JOHN XERS Stock Option (Right to Buy) A - Award D 1.99 215,600 215,600
2021-10-05 2021-10-05 4 JOHNSON JOHN XERS Stock Option (Right to Buy) A - Award D 7.02 31,360 31,360
2021-10-05 2021-10-05 4 JOHNSON JOHN XERS Stock Option (Right to Buy) A - Award D 9.89 31,360 31,360
2021-10-05 2021-10-05 4 JOHNSON JOHN XERS Stock Option (Right to Buy) A - Award D 5.62 31,360 31,360
2021-10-05 2021-10-05 4 JOHNSON JOHN XERS Stock Option (Right to Buy) A - Award D 22.39 10,367 10,367
2021-10-05 2021-10-05 4 JOHNSON JOHN XERS Common Stock A - Award D 478,312 478,312
P
Pasar terbuka atau pembelian swasta atas sekuritas non-derivatif atau derivatif
S
Pasar terbuka atau penjualan pribadi atas sekuritas non-derivatif atau derivatif
A
Hibah, penghargaan, atau perolehan sekuritas lainnya dari perusahaan (seperti opsi)
C
Konversi derivatif
D
Penjualan atau pengalihan surat berharga kembali kepada perusahaan
F
Pembayaran harga pelaksanaan atau kewajiban perpajakan dengan menggunakan sebagian surat berharga yang diterima dari perusahaan
G
Pemberian surat berharga oleh atau kepada insider
K
Swap ekuitas dan transaksi lindung nilai serupa
M
Penggunaan atau konversi sekuritas derivatif yang diterima dari perusahaan (seperti opsi)
V
Suatu transaksi dilaporkan secara sukarela pada Formulir 4
J
Lainnya (disertai catatan kaki yang menjelaskan transaksi)